In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.
Erratum to: Multiple sclerosis (Nature Reviews Disease Primers, (2018), 4, 1, (43), 10.1038/s41572-018-0041-4)
Filippi M.;Preziosa P.;Rocca M. A.
2018-01-01
Abstract
In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
